- Selected Publications
- Team Members
James Barrow, Ph.D. leads the medicinal chemistry, biology, and drug metabolism activities of the group, with the goal of validating novel mechanisms and advancing treatments for disorders of brain development. Dr. Barrow received a B.S. in chemistry from the University of North Carolina, Chapel Hill, graduating with highest honors and highest distinction. He received his Ph.D. from Harvard University, working in the laboratory of Professor David A. Evans, where he completed the total synthesis of zaragozic acids A and C and orienticin C aglycone. He then moved to Merck Research Laboratories in West Point, in the medicinal chemistry department working on a variety of drug discovery projects for cardiovascular and central nervous system disorders. His teams advanced several compounds into clinical development, including MK-8998, which was investigated in phase 2 clinical trials as a potential antipsychotic.
Uslaner JM, Smith SM, Huszar SL, Pachmerhiwala R, Hinchliffe RM, Vardigan JD, Nguyen SJ, Surles NO, Yao L, Barrow JC, Uebele VN, Renger JJ, Clark J, Hutson PH. T-type Calcium Channel Antagonism Produces Antipsychotic-Like Effects and Reduces Stimulant-Induced Glutamate Release in the Nucleus Accumbens of Rats. Neuropharmacology. 62:1413, 2012.
Harrison ST, Mulhearn J, Wolkenberg SE, Miller PJ, O’Malley SS, Zeng Z, Williams DL, Hostetler ED, Sanabria-Bohrquez S, Gammage L, Fan H, Sur C, Culberson JC, Hargreaves RJ, Cook JJ, Hartman GD, Barrow JC. Synthesis and Evaluation of 5-Fluoro-2-aryloxazolo[5,4-b]pyridines as β-Amyloid PET Ligands and Identification of MK-3328. ACS Med. Chem. Lett. 2:498, 2011.
Coleman PJ, Barrow JC. Challenges and Opportunities in Neuroscience Research. Chem Med Chem. 7:339, 2012.
Robinson RG, Smith SM, Wolkenberg SE, Kandebo M, Yao L, Gibson CR, Harrison ST, Polsky-Fisher S, Barrow JC, Manley PJ, Mulhearn JJ, Nanda KK, Schubert JW, Trotter BW, Zhao Z, Sanders JM, Smith RF, McLoughlin D, Sharma S, Hall DL, Walker TL, Kershner JL, Bhandari N, Hutson PH, Sachs NA. Characterization of Non-Nitrocatechol Pan and Isoform Specific Catechol-O-methyltransferase Inhibitors and Substrates. ACS Chemical Neuroscience. 3:129-140, 2012.
Barrow JC. Inhibitors of Catechol-O-Methyltransferase. CNS Neurol. Dis. Drug Tgt. 11:324, 2012.